Companies › Latigo Biotherapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LTG-001 | – | Phase 1 | Healthy | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06049095 | LTG-001 | Phase 1 | Healthy | Other | Sep 2026 |
Cash of $401m on 2026-09-30; operating cash outflow about $91m a year; runway about 53 months at that burn, to Feb 2031
Press releases filed as 8-K in the last year:
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.